ADA 2016 Conference Kickoff and the DiabetesMine D-Data ExChange!

http://type2diabetestreatment.net/diabetes-mellitus/ada-2016-conference-kickoff-and-the-diabetesmine-d-data-exchange/

Today marks the start of the American Diabetes Associations" 76th annual Scientific Sessions, taking place this year in New Orleans -- and also our Summer 2016 DiabetesMine D-Data ExChange, happening now!

As you all surely know, ADA"s giant annual meeting brings together over 15,000 clinicians and healthcare professionals for five days of oral presentations, symposiums, product theater presentations, poster sessions, and of course a huge exhibit hall brimming with all the latest and greatest treatments and products on display.

Yes, there"s an app for that! If you happen to be attending, or just want to browse through event details, download the ADA 2016 app here. There seems to be a bit of confusion over the Twitter hashtag this year (#ADA2016 or #2016ADA) but the @AmDiabetesAssn itself appears to be using #2016ADA, so we recommend going with that.

Our team is on the ground in New Orleans as you read this post, readying for a weekend of frantic D-news activity.

Diabetes Data and Tech News

In the days leading up to this event, we"ve heard word about some of the exciting new announcements being timed with the. A few of those, embargoed until today:

• Data-sharing platform Glooko has announced that it"s almost ready to unveil the Medtronic integration with its platform, the first third-party program that Medtronic has allowed access to its data beyond its own proprietary CareLink platform. The initial announcement of this was big news at last year"s Scientific Sessions, and it"s now nearing the finish line with a planned launch in July. This means easy data-syncing with Minimed pumps and CGM sensors from the Glooko mobile app for iOS and Android, and access to MedT"s CareLink reports directly through Glooko.

• Glooko is also launching a new clinical Advise product that will provide their users insights into blood sugar and insulin use trends -- including "Summary Statistics," "Best Day" and "Time of Day" snapshots, as well as insulin dosing adjustments and pump setting changes.

• Diabetes app developer mySugr is partnering with The Profil Institute, a San Diego-based clinical research organization focused on metabolic diseases. The two will design and conduct clinical research and development programs aimed at "enhancing and validating the clinical and health economic impact of mySugr’s digital health solutions for diabetes management" among the app developer"s user base of more than 700,000 PWDs worldwide, according to the press release. "As part of a multi-year plan, the companies plan to generate, analyze and publish data from prospective and retrospective studies to increase evidence-based research in the field of mobile health app development."

Many more ADA announcements to come starting next week.

Diabetes Science News

Most everything on the science side is embargoed until at least tomorrow, but if you"re wondering what"s much-anticipated in research, last week Medscape published its annual teaser from well-known endocrinologist Dr. Anne Peters of USC Keck School of Medicine. She highlights four things:

• Rumor has it results from the LEADER trial (cardiovascular outcomes trial for liraglutide, being presented on June 13) are positive, "but we don"t know what cardiovascular outcomes were improved in which patients... These results will be very, very important to our understanding of the benefits of GLP-1 receptor agonists on cardiovascular outcomes."

• New data about empagliflozin and other SGLT2 inhibitors (that new class of "pee drug") will be presented at this meeting, which is key because the medical community "still has lots to learn" on the effects of these drugs on the heart, Peters says.

• There will also be a lot of new data on a variety of combo drugs, notably the combination of a GLP-1 receptor agonist and a basal insulin, delivered to patients in a study via injection pen with gradually increasing doses. There"s a lot of excitement about the potential to reduce A1c with minimal side effects.

• And most exciting to us here at the "Mine, results of the DIaMonD trial will come out, which is studying the benefits of (Dexcom) continuous glucose monitor use in T1 patients who are on multiple daily insulins rather than pumps. If good benefits are shown, this is more great fodder for making CGM baseline therapy for all -- and something indispensable that insurance companies will be compelled to cover.

Access Issues at ADA

One of the hottest topics in all corners of the Diabetes Community right now is healthcare costs and access, particularly in light of the controversial United Healthcare decision in May that it would be making Medtronic its exclusive brand of insulin pump -- making it more difficult for UHC members to get new non-MedT pumps starting July 1. Many diabetes orgs and advocates, including ADA, have responded with concern and criticism, warning that restricting patient choice and access is dangerous business.

This will be a big topic of discussion at the ADA conference, although the organization itself hasn"t made it a formal topic – which is unfortunate, given that it"s hosting thousands upon thousands of healthcare providers, advocates, and other influencers. Only a few scheduled sessions focus on the issue of healthcare costs and access, and beyond a simple statement, ADA has declined to offer any detail to date on what it’s doing specifically in response to the emerging #DiabetesAccessMatters protest.

At least the ADA has provided a room to allow a grassroots meeting being pulled together by T1DExchange to take place on Saturday afternoon mid-conference. Titled “Navigating Health Care Through the 21st Century," it will feature several experts talking about health policy changes as a result of ACA (the Affordable Healthcare Act). But at its core, this gathering of advocates will likely be focusing on how to thwart further backroom deals that limit patient choice and stifle innovation. An update will also be provided on what T1D Exchange and JDRF are doing as part of their Health Policy Initiative on access issues announced earlier this year.

The DiabetesMine D-Data ExChange

Meanwhile, today in New Orleans we are hosting our sixth ever DiabetesMine D-Data ExChange event, a gathering of gathering of key innovators in the diabetes technology world. Around 90 participants include representatives from leading Pharma and device companies, DIY innovators developing NightScout and #OpenAPS, the FDA itself and key researchers.

We have a big focus on Artificial Pancreas this time around, as we stand on the exciting precipice of these automated systems finally coming to market!

This should be a very exciting program, covering the gamut of industry, regulatory, academic and patient community DIY perspectives on where closed loop systems stand.

The day’s lineup includes, in this order:

• D-DATA ECOSYSTEMS PANEL – Glooko, Tidepool, DiaSend, One Drop and MySugr discussing various approaches to data viewing, data sharing, and utility for PWDs

• FDA on INTEROPERABILITY & AP DEVELOPMENT – The FDA"s Courtney Lias on regulatory concerns and innovation acceleration efforts

• #OpenAPS and the DRIVE to DIY DIABETES TECHNOLOGY – Citizen hacker Mark Wilson on the power of crowdsourcing and the community’s Call to Action

• ACADEMIC UPDATE – Dr. Trang Ly of Stanford Endocrinology reviewing the Pro’s and Con’s of various AP algorithms, and lessons learned from AP research

• ARTIFICAL PANCREAS PROGRESS FORUM – Updates from leading commercial AP system developers Insulet, Bigfoot Biomed, Dexcom, Medtronic, Animas and Beta Bionics, followed by testimonials from two patients involved in clinical trials

• STRUCTURED BRAINSTORM SESSIONS – A set of expert-led, action-oriented group brainstorm sessions aimed at creating action items for attendees

We"d like to thank our friends at Tidepool for helping to co-organize this event, as well as One Drop for hosting the cocktail reception. Not to mention our 2016 program sponsors starting with our Gold Sponsor Dexcom this year. Thank you all for helping make this patient-led initiative possible as a catalyst for change!

Keep your eyes peeled for the Twitter hashtag #DData16, and feel free to chime in on any topics that interest you.

And stay tuned for more reporting very soon from our team on both #2016ADA and #DData16, of course!

Disclaimer: Content created by the Diabetes Mine team. For more details click here.

Disclaimer

This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn"t adhere to Healthline"s editorial guidelines. For more information about Healthline"s partnership with Diabetes Mine, please click here.

Type 2 Diabetes Treatment
Type 2 Diabetes Diet
Diabetes Destroyer Reviews
Original Article
#DiabetesMellitus